Table 1.
Summary of patient characteristics
| Characteristics | Patients (n = 25) |
|---|---|
| Women, n (%) | 9 (36) |
| Age, y (range) | 61 (31–77) |
| BW, kg (range) | 67 (50–114) |
| BSA, m 2 (range) | 1.8 (1.5–2.2) |
| MTV, cm 3 (range) | 600 (7–6217) |
| Histology, n (%) | |
| Follicular grade 1 | 9 (36) |
| Follicular grade 2 | 4 (16) |
| Diffuse large B‐cell | 12 (48) |
| Ann‐Arbor stage | |
| I | 3 (12) |
| II | 3 (12) |
| III | 8 (32) |
| IV | 11 (44) |
| Chemotherapy, n (%) | |
| RCHOP 21 | 13 (52) |
| RCHOP 14 | 11(44) |
| RDHAP 21 | 1 (4) |
| Dose‐dense, n (%) | 6 (24%) |
BW: body weight; BSA: body surface area; MTV: metabolic tumour volume; RCHOP, rituximab, cyclophosphamide, hydroxy‐doxorubicine, vincristine, prednisone; RDHAP, rituximab, dexamethasone, high‐dose cytarabine, cisplatin; 14 and 21, intercourse duration (days).